- Home
- HG vs RCKT Comparison
HG vs RCKT Comparison
Compare HG & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HG
- RCKT
- Stock Information
- Founded
- HG 2013
- RCKT 1999
- Country
- HG Bermuda
- RCKT United States
- Employees
- HG N/A
- RCKT N/A
- Industry
- HG
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- HG
- RCKT Health Care
- Exchange
- HG Nasdaq
- RCKT Nasdaq
- Market Cap
- HG 1.9B
- RCKT 1.3B
- IPO Year
- HG 2023
- RCKT N/A
- Fundamental
- Price
- HG $18.67
- RCKT $12.72
- Analyst Decision
- HG Buy
- RCKT Strong Buy
- Analyst Count
- HG 7
- RCKT 11
- Target Price
- HG $22.00
- RCKT $50.27
- AVG Volume (30 Days)
- HG 317.6K
- RCKT 1.6M
- Earning Date
- HG 11-06-2024
- RCKT 02-24-2025
- Dividend Yield
- HG N/A
- RCKT N/A
- EPS Growth
- HG 537.51
- RCKT N/A
- EPS
- HG 4.48
- RCKT N/A
- Revenue
- HG $2,266,708,000.00
- RCKT N/A
- Revenue This Year
- HG N/A
- RCKT N/A
- Revenue Next Year
- HG $7.19
- RCKT $233,736.97
- P/E Ratio
- HG $4.15
- RCKT N/A
- Revenue Growth
- HG 68.94
- RCKT N/A
- 52 Week Low
- HG $12.44
- RCKT $11.15
- 52 Week High
- HG $20.71
- RCKT $31.47
- Technical
- Relative Strength Index (RSI)
- HG 47.32
- RCKT 47.75
- Support Level
- HG $18.38
- RCKT $11.56
- Resistance Level
- HG $19.24
- RCKT $12.32
- Average True Range (ATR)
- HG 0.54
- RCKT 0.71
- MACD
- HG -0.04
- RCKT 0.20
- Stochastic Oscillator
- HG 37.60
- RCKT 66.81
About HG Hamilton Insurance Group Ltd. Class B
Hamilton Insurance Group Ltd is a specialty insurance and reinsurance company. It operates globally, with underwriting operations in Lloyd's, Ireland, Bermuda, and the United States. It operates three principal underwriting platforms (Hamilton Global Specialty, Hamilton Select and Hamilton Re) that are categorized into two reporting business segments: International and Bermuda.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.